Meeting
2016 Gastrointestinal Cancers Symposium
Clinical and molecular assessment of response to regorafenib.
Authors
Nao Kakizawa
Saitama Medical Center, Jichi Medical University, Saitama, Japan
Nao Kakizawa , Koichi Suzuki , Yuji Takayama , Kosuke Ichida , Taro Fukui , Fumiaki Watanabe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 568)
DOI
10.1200/jco.2016.34.4_suppl.568
Abstract #
568
Poster Bd #
D17
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Circulating tumor DNA (ctDNA) as an early marker to monitor clinical benefit of regorafenib and TAS-102 in patients with metastatic colorectal cancer (mCRC).
First Author: Allan Andresson Lima Pereira
Poster
2018 Gastrointestinal Cancers Symposium
Dynamics and characteristics of KRAS mutated circulating tumor DNA in patients with metastatic colorectal cancer during various treatments.
First Author: Yuji Takayama
Poster
2018 Gastrointestinal Cancers Symposium
A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HGCSG1503): Analysis of cases of prior regorafenib.
First Author: Atsushi Ishiguro
Poster
2016 Gastrointestinal Cancers Symposium
Regorafenib for previously treated metastatic colorectal cancer (mCRC): A subgroup analysis of 364 patients in the USA treated in the international, open-label phase IIIb CONSIGN study.
First Author: Udit Verma